Home » FDA Approves Dose of Lupin’s Budesonide Inhalation Suspension
FDA Approves Dose of Lupin’s Budesonide Inhalation Suspension
November 20, 2018
Lupin received another approval from the FDA for its Budesonide inhalation suspension, a generic version of AstraZeneca’s long-term maintenance treatment, Pulmicort Respules, used to control and prevent asthma symptoms in children.
The agency approved the 0.5mg/2 mL single-dose ampules of Budesonide’s inhalation suspension for use in children 12 months to eight years of age.
The generic is not an adequate treatment for a severe asthma attack and should only be used with a jet nebulizer device connected to an air compressor, the agency said.
Upcoming Events
-
21Oct